Intensive 7+3 induction for secondary/blast-phase AML

Current understanding

To be populated as evidence accumulates.

2026-07-18 — Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.: Large contemporary Mayo Clinic observational series (NGS-annotated) confirmed dismal 7+3 outcomes for post-MPN AML (27% CR/CRi, 0% 5-year transplant-censored OS) versus post-MDS/MDS-MPN AML (64% CR/CRi, 21% 5y OS) and primary non-CBF AML (76% CR/CRi, 57% 5y OS), and found that NGS-based mutation risk stratification was informative primarily in primary non-CBF AML rather than in post-MPN AML. (novelty: 3)